![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed under File No. 333-280796. The company, headquartered in Washington, D.C., seeks to have the Registration Statement become effective at 9:00 a.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable. This request, made pursuant to Rule 461 of the Securities Act of 1933, comes with the acknowledgment from the company that the SEC's declaration of effectiveness does not preclude further SEC action regarding the Registration Statement, nor does it absolve the company of its responsibility for the adequacy of the disclosure within the Registration Statement. The company also recognizes that it cannot use the SEC's comments or the effectiveness of the Registration Statement as a defense in any legal proceedings. Upon effectiveness, 60 Degrees Pharmaceuticals has requested oral confirmation from the SEC and a written order verifying the effective time and date to be sent to their counsel, Sichenzia Ross Ference Carmel LLP.
60 Degrees Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed under File No. 333-280796. The company, headquartered in Washington, D.C., seeks to have the Registration Statement become effective at 9:00 a.m. Eastern Time on July 18, 2024, or as soon thereafter as practicable. This request, made pursuant to Rule 461 of the Securities Act of 1933, comes with the acknowledgment from the company that the SEC's declaration of effectiveness does not preclude further SEC action regarding the Registration Statement, nor does it absolve the company of its responsibility for the adequacy of the disclosure within the Registration Statement. The company also recognizes that it cannot use the SEC's comments or the effectiveness of the Registration Statement as a defense in any legal proceedings. Upon effectiveness, 60 Degrees Pharmaceuticals has requested oral confirmation from the SEC and a written order verifying the effective time and date to be sent to their counsel, Sichenzia Ross Ference Carmel LLP.
60度製藥公司已正式向美國證券交易所(SEC)請求加速生效其S-3表格的註冊聲明,最初在文件號333-280796下提出。總部位於華盛頓特區的公司希望註冊聲明在2024年7月18日美國東部時間上午9點或儘快生效。根據1933年證券法規則461,該請求是基於公司承認SEC的生效聲明並不排除關於註冊聲明的進一步SEC行動,也不免除公司對註冊聲明中披露充分性的責任。公司還意識到,它不能將SEC的評論或註冊聲明的效力作爲任何法律訴訟的辯護。60度製藥公司在生效後,請求SEC口頭確認並向他們的律師Sichenzia Ross Ference Carmel LLP發送一份確認生效時間和日期的書面命令。
60度製藥公司已正式向美國證券交易所(SEC)請求加速生效其S-3表格的註冊聲明,最初在文件號333-280796下提出。總部位於華盛頓特區的公司希望註冊聲明在2024年7月18日美國東部時間上午9點或儘快生效。根據1933年證券法規則461,該請求是基於公司承認SEC的生效聲明並不排除關於註冊聲明的進一步SEC行動,也不免除公司對註冊聲明中披露充分性的責任。公司還意識到,它不能將SEC的評論或註冊聲明的效力作爲任何法律訴訟的辯護。60度製藥公司在生效後,請求SEC口頭確認並向他們的律師Sichenzia Ross Ference Carmel LLP發送一份確認生效時間和日期的書面命令。
有用
沒用
該公告為獨立文件:
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了